JAS239 是一种可透过血脑屏障的 ChoK 抑制剂,可抑制磷酸胆碱合成并降低 E2F1 蛋白表达水平,具有近红外荧光特性,对胶质母细胞瘤表现出抗肿瘤活性,可用于胶质母细胞瘤的相关研究。
JAS239
产品编号: MS-T62313 分子式: C31H37ClN2O2 分子量: 505.09
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

JAS239 是一种可透过血脑屏障的 ChoK 抑制剂,可抑制磷酸胆碱合成并降低 E2F1 蛋白表达水平,具有近红外荧光特性,对胶质母细胞瘤表现出抗肿瘤活性,可用于胶质母细胞瘤的相关研究。

生物实验数据

生物活性 JAS239 is a blood-brain barrier-permeable ChoK inhibitor that inhibits phosphocholine synthesis and downregulates E2F1 protein expression, exhibits near-infrared fluorescence properties, and possesses antitumor activity against glioblastoma, making it suitable for research related to glioblastoma.
IC50 & Target

ChoK

 

E2F1

 

体外研究
(In Vitro)

JAS239 (100 μM max; 24 h) 可降低胶质母细胞瘤 (GBM) 细胞的代谢活性 (细胞活力的替代指标),在常氧和低氧条件下对 F98、9L、U-87 MG 和 U-251 MG 细胞系的作用效力相近。
JAS239 (500 nM; 24-96 h) 可通过诱导细胞周期阻滞并下调 E2F-1 表达来抑制 GBM 细胞的增殖。
JAS239 (500 nM; 0-96 h) 可在常氧条件下抑制 9L 胶质母细胞瘤细胞系的增殖。

Cell Invasion Assay

Cell Line: rat F98, human U-87 MG GBM cell lines (3D spheroid assay); rat F98, 9L, human U-251 MG GBM cell lines (integrin expression analysis)
Concentration: 500 nM
Incubation Time: 16 h (3D spheroid assay)
Result: Significantly reduced track straightness (0.28 ± 0.11 vs.
0.32 ± 0.12, p < 0.0001), track length (84.0 ± 48.0 μm vs.
113.2 ± 86 μm, p < 0.0001), and average speed (0.005 ± 0.001 μm/s vs.
0.007 ± 0.004 μm/s, p < 0.0001), and induced super-diffusive cell motion in normoxic F98 spheroids.
Significantly reduced track straightness and length, and increased cell speed, with induced super-diffusive cell motion in DMOG-hypoxic F98 spheroids.
Significantly increased track length (133.0 ± 61.6 μm vs.
120.7 ± 57.7 μm, p < 0.001) and average speed (0.007 ± 0.001 μm/s vs.
0.006 ± 0.001 μm/s, p < 0.0001), with no change in track straightness, and induced super-diffusive cell motion in normoxic U-87 MG spheroids.
Resulted in track straightness and speed comparable to DMOG-only treatment, with induced super-diffusive cell motion in DMOG-hypoxic U-87 MG spheroids.
Reduced integrin α3β1 protein expression (a marker of cell mobility) in F98, 9L, and U-251 MG cells.
体内研究
(In Vivo)

JAS239 (4 mg/kg;腹腔注射;每日 1 次;连续 5 天) 可抑制胶质母细胞瘤大鼠和小鼠的肿瘤生长。

Animal Model: Fischer F344 (female, weight 100-120 g, intracranial injection of 50,000 F98 GBM cells)
Dosage: 4 mg/kg
Administration: intraperitoneal injection; once daily; 5 consecutive days
Result: Significantly reduced tumor growth (p < 0.05) and percentage change of tumor volume (p = 0.033) compared to controls.
Detected a significant reduction (p = 0.02) in mI/tCr ratio in treated tumors.
Noted a 32% non-significant reduction in Glx/tCr ratio.
Observed a near-significant 97% increase (p = 0.052) in (Lip + Lac)/tCr ratio.
Measured a near-significant lower mitotic index (p = 0.06) in treated tumors.
Showed non-significant reduction in tCho/tCr ratio and non-significant trend of reduction in tCho/NAA ratio.
Animal Model: Fischer F344 (female, weight 100-120 g, intracranial injection of 100,000 9L GBM cells)
Dosage: 4 mg/kg
Administration: intraperitoneal injection; once daily; 5 consecutive days
Result: Observed non-significant tumor growth arrest compared to controls.
Measured the largest non-significant reduction in tCho/tCr ratio (-42%) across all models.
Detected a significant reduction (p = 0.047) in tCho/NAA ratio.
Showed non-significant trend of reduction in mI/tCr ratio and Glx/tCr ratio.
Observed a non-significant -20% change in (Lip + Lac)/tCr ratio.
Measured a lower mitotic index in treated tumors.
Animal Model: C57BL/6 (male, age 8-10 weeks, weight 20-25 g, intracranial injection of 500,000 GL261 GBM cells)
Dosage: 4 mg/kg
Administration: intraperitoneal injection; once daily; 5 consecutive days
Result: Observed non-significant tumor growth arrest compared to controls.
Showed non-significant reduction in tCho/tCr ratio and non-significant trend of reduction in tCho/NAA ratio.
Detected non-significant trend of reduction in mI/tCr ratio.
Noted no significant change in Glx/tCr ratio and (Lip + Lac)/tCr ratio.
Measured a lower mitotic index in treated tumors.

化学信息

分子量 505.09
分子式 C31H37ClN2O2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础